Eliquis Apizaban
warning-circle
This information is intended for healthcare professionals based in Ireland. If you are not a healthcare professional in Ireland, click here

    SmPC

Prescribing Information

Risk Minimisation Material

Made in Irealand

500

foot note heading

Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance at www.hpra.ie
Adverse reactions should also be reported to Bristol Myers Squibb Medical Information on 1 800 749 749 or medical.information@bms.com

Eliquis Apizaban

You may contact our EU Data Protection Officer at EUDPO@BMS.com to exercise any data privacy rights that you may have, as well as to raise or questions in relation to the handling of your personal data by Bristol Myers Squibb Company.

© 2025 Bristol Myers Squibb Company

All corporate names and logos of BMS and/or its products are trademarks of Bristol Myers Squibb Company and are protected by national and intellectual and industrial property laws. All rights reserved over the content of this website. Your use of this website is subject to the Legal Notice, Privacy and Cookie Policy, the Pharmacovigilance Notice and the applicable laws and regulations.

Home   Site Map   Privacy Policy   Cookie Preferences   Legal Notice   Pharmacovigilance Notice   Get in Touch

bms-pfizer_alliance_logo